好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

A Natural Language Algorithm Identifies Multiple Sclerosis Relapses from Clinical Notes With High Sensitivity
Multiple Sclerosis
P3 - Poster Session 3 (5:30 PM-6:30 PM)
15-002

To develop, refine and test a natural language processing (NLP) algorithm to extract multiple sclerosis (MS) relapses (MS  Relapse  Sentiment Algorithm) from clinical notes with high sensitivity.



Clinical relapses in MS have been dramatically reduced by effective therapies, but remain a focus of scientific inquiries (e.g. natural history, health economics). Historically, these relapses were recorded as unstructured data in clinical  notes,  requiring  time-consuming review of the electronic medical record (EMR) for extraction.

A combination of string matching, sentiment analysis and classification were implemented to identify MS relapses from three sets of notes for patients seen in the UCSF MS Center. The training set included 500 notes from research participants (relapses recorded annually); validation set included 450 notes from women aged 18-50 (high relapse rates); test set included 150 notes from the latter group and 250 notes from patients beginning anti-CD20 therapy (relapsing and progressive MS). Altogether, the notes spanned 502 patients, 13 years (2005-2018), and 14 clinicians. Algorithms were developed to extract relevant information from long notes, which were then passed into a Naïve Bayes probabilistic classifier that determined whether or not a note indicated a relapse. This output was compared to categorizations made by manual review for MS expert indication of clinical relapse since prior visit.

In the final test set (400 notes), the algorithm correctly identified 47/48 relapses (sensitivity = 97.9%). Negative predictive value was 99.6% (274/275 notes). However, positive predictive value was 37.6% (47/125) and specificity was 78%. The NLP algorithm classified an additional 3,000 notes in <1 minute, identifying possible relapses in <1/3 of notes.

The MS Relapse Sentiment Algorithm could rapidly scan a clinic’s historical EMR notes with high sensitivity, allowing researchers to focus their manual review for false positives in the lower proportion of notes marked as clinical relapses.

Authors/Disclosures

PRESENTER
No disclosure on file
Chelsea S. Chen Ms. Chen has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Jeffrey M. Gelfand, MD, MS, FAAN (University of California, San Francisco) Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.
No disclosure on file
No disclosure on file
No disclosure on file
Riley Bove, MD, FAAN (University of California, San Francisco) Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amgen. Dr. Bove has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genzyme-Sanofi. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Bove has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD-Serono. Dr. Bove has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cadenza. The institution of Dr. Bove has received research support from Biogen. The institution of Dr. Bove has received research support from Eli Lilly. The institution of Dr. Bove has received research support from Novartis. The institution of Dr. Bove has received research support from Roche Genentech.